...
首页> 外文期刊>The American heart journal >Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators
【24h】

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators

机译:来自患有心房颤动的非维生素K拮抗剂口腔抗凝血剂的枢轴随机对照试验的个体患者数据(结合AF):从组合AF的设计和理论(多种机构之间的合作,以更好地调查非维生素K拮抗剂口腔抗凝血剂 在心房颤动中使用)调查员

获取原文
获取原文并翻译 | 示例
           

摘要

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred class of medications for prevention of stroke and systemic embolism in patients with atrial fibrillation unless contraindications exist. Five large, international, randomized, controlled trials of NOACs versus either warfarin or aspirin have been completed to date.
机译:背景非维生素K拮抗剂口服抗凝剂(NOAC)是预防房颤患者卒中和全身性栓塞的首选药物,除非存在禁忌症。迄今为止,已经完成了五项关于NOACs与华法林或阿司匹林的大型国际随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号